Skip to content
Peptide research

Cortistatin

Also known as Cortistatin-14 · CST-14
Category
Brain & Cognition
Administration routes
Injectable
Regulatory status
Not FDA-approved

What it is

A neuropeptide related to somatostatin, explored for sleep, anti-inflammatory, and pain effects. The case rests almost entirely on animal and mechanism studies; human evidence is minimal to absent, so benefits remain speculative. It shares somatostatin's growth-hormone suppression, may cause GI effects, and has essentially no human safety data. Not an approved drug in the US, and supply is unregulated research-grade product of uncertain purity.

Read Full record

Studied uses & evidence

Studied uses(5)

  • Enhancement of slow-wave sleep via non-somatostatin receptor mechanisms

    Low

    Deep sleep effects confirmed in rats; underlying receptor differs from somatostatin, not fully identified.

  • Potent anti-inflammatory effects — suppresses TNF-alpha, IL-6, IL-12 in multiple disease models

    Low

    Reduces inflammatory markers across multiple animal disease models; no human studies exist.

  • Inhibition of vascular smooth muscle cell proliferation and neointimal hyperplasia

    Low

    Shown in human cells and mouse models; a single study, no human dosing trials.

Evidence limits

Evidence Level
Preclinical

Cortistatin research is predominantly preclinical, with strong evidence for anti-inflammatory, sleep-promoting, cardiovascular protective, and neuroprotective effects in animal models. At least four small human studies have been conducted (Broglio et al. 2002-2004, Giordano et al. 2006), demonstrating cortistatin's endocrine effects via IV infusion in healthy volunteers and patients with acromegaly or prolactinoma. No large-scale Phase II/III therapeutic trials have been completed. The peptide's unique receptor profile (binding both somatostatin receptors and the ghrelin receptor) suggests therapeutic potential distinct from somatostatin analogs like octreotide.

Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)

Cautions & risk summary

Do not use if

  • Diabetes or hypoglycemia risk

    Moderate

    Like somatostatin, cortistatin inhibits insulin and glucagon secretion. Can disrupt glucose homeostasis.

  • Growth hormone deficiency

    Moderate

    Cortistatin suppresses GH secretion similarly to somatostatin. May worsen GH deficiency.

General cautions

  • Pregnancy

    Absolute

    No human safety data. Pleiotropic effects on multiple receptor systems make risk unpredictable.

Risk summary(3)

Risks = level of concern: High · Moderate · Low · Theoretical

  • Suppression of growth hormone secretion (shared with somatostatin)

    Moderate
  • Potential gastrointestinal effects from somatostatin receptor activation

    Moderate
  • Minimal human safety data available

    High
Safety & interactions in Full record

Further reading

Read Full record

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.